Theranos Raised Nine Hundred Million Without a Working Product
A blood testing company reached a nine billion dollar valuation on technology that did not function. The investor list explains more about the failure than the science does.
The Claim
Theranos claimed to have developed technology performing a wide range of diagnostic tests from a very small blood sample, replacing conventional venous draws. If it had worked, the implications for diagnostics would have been substantial.
The company raised roughly nine hundred million dollars and reached a valuation around nine billion. The technology did not work as described, and the company ultimately ran many tests on conventional third party equipment while presenting results as its own.
Who Invested and Who Did Not
The most instructive fact concerns the investor base. Backers included prominent individuals, family offices, and a media organisation, alongside a board unusually heavy with former government and military figures.
Notably absent were the specialist venture funds that invest in diagnostics and life sciences. Those firms employ people with scientific training who conduct technical diligence, and several reportedly examined the opportunity and declined.
The people best equipped to evaluate the technology largely passed. The people who invested were mostly evaluating something other than the technology.
Why the Board Was a Warning
A board composed of eminent figures without relevant technical expertise is frequently presented as validation, and it functions as the opposite.
A board's role includes challenging management on the substance of the business. Directors distinguished in diplomacy or defence cannot assess whether a diagnostic claim is plausible, so the challenge function is absent while the appearance of oversight is strong.
The correct question about any board is not how impressive the members are but whether they collectively possess the expertise to know when they are being misled about the core activity.
The Structural Difference From Software
An important nuance is why this failure mode is more available in some sectors than others. A software company that does not work is discovered quickly, because users interact with the product directly.
Diagnostics is different. Results are produced by instruments most people cannot evaluate, in laboratories they cannot enter, verified by processes they do not understand. The gap between claim and verification is wide and requires expertise to close.
Secrecy justified as protecting intellectual property extended that gap further. Trade secret protection is legitimate, and it also prevents exactly the external validation that would have surfaced the problem.
The Consequence That Mattered Most
Because the tests were used on actual patients through a retail pharmacy partnership, inaccurate results had clinical consequences. That distinguishes it from failures where investors lose money and nothing else occurs.
The founder was convicted on multiple counts of fraud and sentenced to prison, as was the former president of the company.
The Transferable Test
The practical question for evaluating any technical claim is whether independent parties with relevant expertise have verified it under conditions they controlled.
Peer reviewed publication, regulatory clearance based on submitted data, or independent testing all serve that function. Testimonials, impressive boards, and high profile partnerships do not, because none of them require the technology to work.
The Bottom Line
Theranos raised money from people who could not evaluate the science after people who could had declined. Ask who verified the core claim and what access they were given.